Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion

Archives of Gynecology and Obstetrics

Volumn 286, Issue 6, 2012, Pages 1537-1543

  Hu, Xiaoxia ^a   Li, Danrong ^b   Zhang, Wei ^b   Zhou, Jie ^b   Tang, Bujian ^b   Li, Li ^b  

^a People's Hospital of Guangxi Province   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Invasion; Matrix metalloproteinase; Ovarian cancer; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MESSENGER RNA; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADOLESCENT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL FUNCTION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL RATE; SURVIVAL TIME; ADULT; BLOOD; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; TUMOR INVASION;

ADOLESCENT; ADULT; AGED; CELL ADHESION; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; YOUNG ADULT;

EID: 84877608652     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-012-2456-6     Document Type: Article

References (26)

1. Zagouri F, Dimopoulos MA, Bournakis E, Papadimitriou CA (2010) Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol 31:268-277
2. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67
3. Stallings-Mann M, Radisky D (2007) Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells Tissues Organs 185:104-110
4. Cruz-Munoz W, Khokha R (2008) The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 45:291-338
5. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157-166
6. Rauvala M, Aglund K, Puistola U, Turpeenniemi-Hujanen T, Horvath G, Willén R, Stendahl U (2006) Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression. Int J Gynecol Cancer 16:1297-1302
7. Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Daraï E (2006) Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 16:1911-1917
8. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M (2003) Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24:1417-1420
9. Schmalfeldt B, Prechtel D, Harting K et al (2001) Increased expression of matrix metalloproteinases (MMP)-2, MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7:2396-2404
10. Brun JL, Cortez A, Commo F, Uzan S, Uzan S, Rouzier R, Daraï E (2008) Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 33:1239-1246
11. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood) 231:20-27
12. Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J, Haglund C (2010) MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol 31:149-155
13. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, Shriver CD (2006) Circulating MMP2 and MMP9 in breast cancer potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 119:1403-1411
14. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T (2007) Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer 97:971-977
15. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC (2008) Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 122:2050-2056
16. Manenti L, Paganoni P, Floriani I et al (2003) Expression levels of vascular endothelial growth factor, matrix metalloproteinases-2 and -9 and tissue inhibitor of metalloproteinases-1 and -2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39:1948-1956
17. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M (2007) Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res 27:2753-2758
18. Lengyel E, Schmalfeldt B, Konik E et al (2001) Expression of latent matrix metalloproteinase-9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82:291-298
19. Sakata K, Shigemasa K, Nagai N, Ohama K (2000) Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17:673-681
20. Kamat AA, Fletcher M, Gruman LM et al (2006) The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12:1707-1714
21. Gershtein ES, Levkina NV, Digayeva MA, Laktionov KP, Tereshkina IV, Kushlinsky NE (2010) Matrix metalloproteinases-2, -7, and -9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bull Exp Biol Med 149:628-631
22. Sillanpää S, Anttila M, Suhonen K et al (2007) Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 in epithelial ovarian cancer. Tumour Biol 28:280-289
23. Sillanpää S, Anttila M, Voutilainen K et al (2007) Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104:296-303
24. Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Daraï E (2011) Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncol Rep 27(4):1049-1057
25. Wang FQ, So J, Reierstad S, Fishman DA (2005) Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer 114:19-31
26. Sillanpää SM, Anttila MA, Voutilainen KA, Ropponen KM, Sironen RK, Saarikoski SV, Kosma VM (2006) Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression. Int J Cancer 119:1792-1799